Transfusion-associated graft versus host disease medical therapy

Transfusion-associated graft versus host disease Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Transfusion-associated graft versus host disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Biomarker Panel
Chest X Ray
HLA analysis
Skin Punch Biopsy
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Transfusion-associated graft versus host disease medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Transfusion-associated graft versus host disease medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Transfusion-associated graft versus host disease medical therapy
CDC on Transfusion-associated graft versus host disease medical therapy
Transfusion-associated graft versus host disease medical therapy in the news
Blogs on Transfusion-associated graft versus host disease medical therapy
Directions to Hospitals Treating Transfusion-associated graft versus host disease
Risk calculators and risk factors for Transfusion-associated graft versus host disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Treatment is only supportive, as no available form of therapy has proven effective in treating TA-GvHD.